These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34254894)

  • 1. Landscape and progress of global COVID-19 vaccine development.
    Huang HY; Wang SH; Tang Y; Sheng W; Zuo CJ; Wu DW; Fang H; Du Q; Li N
    Hum Vaccin Immunother; 2021 Oct; 17(10):3276-3280. PubMed ID: 34254894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coronavirus disease 2019 vaccines: landscape of global studies and potential risks.
    Jiang HD; Tao YY; Jia SY; Li JX; Zhu FC
    Chin Med J (Engl); 2021 Aug; 134(17):2037-2044. PubMed ID: 34343152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines.
    Nascimento Júnior JAC; Santos AM; Cavalcante RCM; Quintans-Júnior LJ; Walker CIB; Borges LP; Frank LA; Serafini MR
    Drug Dev Ind Pharm; 2021 Apr; 47(4):673-684. PubMed ID: 33826439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Latest updates on COVID-19 vaccines.
    Li Q; Lu H
    Biosci Trends; 2021 Jan; 14(6):463-466. PubMed ID: 33390384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expert recommendation for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients with HIV infection].
    AIDS and Hepatitis C Professional Group, Chinese Society of Infectious Diseases
    Zhonghua Nei Ke Za Zhi; 2021 Jul; 60(7):615-618. PubMed ID: 34619837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19.
    Li Q; Wang J; Tang Y; Lu H
    Drug Discov Ther; 2021; 15(3):118-123. PubMed ID: 34234059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human and novel coronavirus infections in children: a review.
    Rajapakse N; Dixit D
    Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Super-rapid race for saving lives by developing COVID-19 vaccines.
    Uttarilli A; Amalakanti S; Kommoju PR; Sharma S; Goyal P; Manjunath GK; Upadhayay V; Parveen A; Tandon R; Prasad KS; Dakal TC; Ben Shlomo I; Yousef M; Neerathilingam M; Kumar A
    J Integr Bioinform; 2021 Mar; 18(1):27-43. PubMed ID: 33761582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine Strategy During the SARS-CoV-2 Pandemic: What School Nurses Need to Know.
    Barnby E; Reynolds M; Gordon J
    NASN Sch Nurse; 2021 Nov; 36(6):316-322. PubMed ID: 34060925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Consolidated recommendations of the Advisory Committee on Vaccines and Immunization Strategies- on prioritizing COVID-19 vaccination].
    Dabanch J; Bastías M; Endeiza ML; Díaz E; Inostroza J; Cerda J; Santillana S; Rodríguez J; González C; Rodríguez M; Pizarro A
    Rev Chilena Infectol; 2021 Apr; 38(2):185-188. PubMed ID: 34184708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein-based nano-vaccines against SARS-CoV-2: Current design strategies and advances of candidate vaccines.
    Wang D; Yuan Y; Liu B; Epstein ND; Yang Y
    Int J Biol Macromol; 2023 May; 236():123979. PubMed ID: 36907305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On Setting Expectations for a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.
    Canaday DH; Gravenstein S
    Clin Infect Dis; 2021 Feb; 72(3):513-514. PubMed ID: 33527123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multisystem Inflammatory Syndrome after SARS-CoV-2 Infection and COVID-19 Vaccination.
    Salzman MB; Huang CW; O'Brien CM; Castillo RD
    Emerg Infect Dis; 2021 Jul; 27(7):1944-1948. PubMed ID: 34034858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targets and strategies for vaccine development against SARS-CoV-2.
    Malik JA; Mulla AH; Farooqi T; Pottoo FH; Anwar S; Rengasamy KRR
    Biomed Pharmacother; 2021 May; 137():111254. PubMed ID: 33550049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination against SARS-CoV-2 and disease enhancement - knowns and unknowns.
    Zellweger RM; Wartel TA; Marks F; Song M; Kim JH
    Expert Rev Vaccines; 2020 Aug; 19(8):691-698. PubMed ID: 32838605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune imprinting and SARS-CoV-2 vaccine design.
    Wheatley AK; Fox A; Tan HX; Juno JA; Davenport MP; Subbarao K; Kent SJ
    Trends Immunol; 2021 Nov; 42(11):956-959. PubMed ID: 34580004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.